Quick answerAcross documented research protocols, the 80 mg KLOW blend vial is commonly reconstituted with 3 mL of bacteriostatic water, with the research literature referencing approximately 2667 mcg per dose measured from that reconstituted solution. These numbers characterize reported research handling and are shared solely for research-use-only, non-clinical purposes.
Fixed ratio: GHK-Cu 50 mg : BPC-157 10 mg : TB-500 10 mg : KPV 10 mg — a 5:1:1:1 blend. Every withdrawal keeps that ratio, so the components cannot be dosed independently.
Reconstitution calculator
Mix & measure KLOW · 80 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Vial strengthmgBAC watermLYour dose
Concentration—mg/mL
Draw volume—mL
On the syringe—units
Doses / vial—
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
One combined 80 mg vial, dosed by total blend — step by step
Standard / Gradual Approach (3 mL = ~26.67 mg/mL)
All four peptides sit in the same 80 mg vial, so every unit drawn delivers the fixed blend ratio: 62.5% GHK-Cu and 12.5% each of BPC-157, KPV and TB-500. The figures below are total-blend micrograms; the per-component amounts follow automatically and cannot be tuned on their own.
▪
Reconstitute: Add 3.0 mL bacteriostatic water to the one 80 mg vial → final concentration ~26.67 mg/mL of total blend, where 1 unit ≈ 267 mcg.
▪
Convert: units = total mcg ÷ 267. Once-daily subcutaneous injection for 8–12 weeks, optionally extended to ~16 weeks.
Phase / Week(s) Total Blend Dose (1× daily) Volume (U-100 units / mL) Weeks 1–2 2,667 mcg total ~10 units (0.10 mL) Weeks 3–6 4,000 mcg total ~15 units (0.15 mL) Weeks 7–12 5,333 mcg total ~20 units (0.20 mL)
Ask what generic AI won't
ChatGPT dodges your KLOW dosing questions. OpenPeptide answers them.
Documented protocols, exact reconstitution math, and real sources — no lectures, no dead ends.
Why researchers study it
Why KLOW draws research interest
These are the directions researchers and the peptide community most often explore KLOW for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Tissue repair & recovery
Explored in preclinical research on soft-tissue and muscle repair — the reason these four peptides are combined; not clinically validated.
Wound & injury healing
Each peptide individually studied in animal models of wound closure and injury recovery; the blended combination itself stays investigational, not approved.
Inflammation modulation
KPV and BPC-157 investigated for anti-inflammatory activity in preclinical gut and tissue models; the blend's effect is not established.
Skin & collagen support
GHK-Cu researched in cosmetic and preclinical work on collagen and skin repair; the multi-peptide mixture has no equivalent human data.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
01 · At a glance
What is KLOW (GHK-Cu, KPV, BPC-157, TB-500)?
KLOW is a single 80 mg vial holding four research peptides blended together in one fixed ratio: GHK-Cu 50 mg, BPC-157 10 mg, KPV 10 mg and TB-500 10 mg[1][5]. Because all four share one vial, they are reconstituted and dosed together — the components cannot be adjusted independently. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. Every component is an unapproved research chemical, not a medicine, and the four-peptide combination has not been validated by any human trial — presented for research and educational use only.
Reconstitute
Add 3.0 mL bacteriostatic water to the one 80 mg vial → ~26.67 mg/mL total blend. At this dilution 1 unit ≈ 267 mcg of combined peptide.
Daily range
2,667–5,333 mcg of total blend once daily, titrated upward gradually across an 8–12 week course (about 10–20 units).
Easy measuring
At ~26.67 mg/mL, 10 units ≈ 2,667 mcg, 15 units ≈ 4,000 mcg and 20 units ≈ 5,333 mcg on a U-100 syringe.
Storage
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
i
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
02 · Dosing & reconstitution
Per-component breakdown (fixed ratio). At the 10-unit starting dose, 2,667 mcg of total blend works out to roughly 1,667 mcg GHK-Cu plus ~333 mcg each of BPC-157, KPV and TB-500. The same 62.5 / 12.5 / 12.5 / 12.5 split scales up at 15 and 20 units.
Frequency: one subcutaneous injection each day, titrating up as tolerated. These figures come from how the fixed-ratio blend reconstitutes, not from any approved human dosing of the combination[3][4].
How to reconstitute KLOW, step by step
1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
2
Release it slowly down the vial’s inner wall to limit foaming.
3
Swirl or roll gently until the blend is fully dissolved — don’t shake.
4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Note
Because all four peptides share one vial, you reconstitute and dose the blend as a single solution; the ratio between components is fixed and cannot be changed. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptides.
How do you hit a 2 mg GHK-Cu dose with KLOW?
A common question about KLOW is how to line it up with the GHK-Cu protocols that step up to 2.0 mg per dose. Because KLOW is a fixed 5:1:1:1 blend, you do not dose GHK-Cu directly — you pick the draw whose GHK-Cu fraction lands on 2 mg, and accept the rest of the blend that comes with it. Here is what that draw actually is.
Component Share of the 80 mg vial Dose delivered Volume (U-100 units / mL) GHK-Cu 50 mg (62.5%) 2,000 mcg (2.0 mg) BPC-157 10 mg (12.5%) 400 mcg (0.4 mg) TB-500 10 mg (12.5%) 400 mcg (0.4 mg) KPV 10 mg (12.5%) 400 mcg (0.4 mg) Total blend 80 mg 3,200 mcg (3.2 mg) 12 units (0.12 mL)
The volume is listed once because there is only one: a single 12-unit (0.12 mL) injection delivers all 4 peptides together, in the vial’s fixed 5:1:1:1 ratio. The per-component rows are what that one draw contains — not separate injections.
▪The draw: 12 units (0.12 mL) on a U-100 syringe, from the standard 3.0 mL mix documented on this page. ▪Why 12 units: the 80 mg vial holds 50 mg of GHK-Cu, so after 3.0 mL of bacteriostatic water the GHK-Cu alone sits at ~16.67 mg/mL — about 167 mcg per unit. That is the same GHK-Cu concentration as a standalone GHK-Cu 50 mg vial mixed with 3 mL, which is why the draw is the same 12 units. ▪Against this page’s chart: 12 units sits between the first two steps of the chart above: Weeks 1–2 (10 units) carries about 1,667 mcg of GHK-Cu, and Weeks 3–6 (15 units) carries about 2,500 mcg of GHK-Cu. ▪Vial longevity: a 0.12 mL draw gives 25 doses per 80 mg vial — about 25 days at once daily, or roughly 8 weeks at three times weekly. ▪What rides along: the ratio is fixed, so the same draw also delivers 400 mcg of each other peptide in the vial. You cannot raise GHK-Cu without raising them.
i
If GHK-Cu is the only goal, this is the indirect route. A KLOW vial cannot be dosed one peptide at a time — hitting 2 mg of GHK-Cu forces 400 mcg of every other component along with it. Researchers targeting GHK-Cu on its own use a single-peptide vial instead: the GHK-Cu 50 mg dosage protocol reaches the same 2.0 mg at the same 12 units, with nothing else in the syringe. Neither route is approved for human use.
03 · What you’ll need
What do you need to reconstitute KLOW?
Quantities below assume an 8–16 week course of once-daily injections with gradual titration. One 80 mg KLOW vial reconstituted to 3.0 mL covers roughly 15–30 daily doses depending on the phase.
✓KLOW Blend Vials (80 mg combined)
One vial reconstituted to 3.0 mL lasts about 15–30 days; plan extra to cover the full cycle.
8 weeks: ~2–3 vials 12 weeks: ~3–4 vials 16 weeks: ~4–5 vials
✓Insulin Syringes (U-100, 1 mL)
Per injection: 1 syringe 8 weeks (once daily): ~56 syringes 16 weeks (once daily): ~112 syringes
✓Bacteriostatic Water (10 mL bottles)
Use ~3.0 mL per 80 mg vial for reconstitution.
8 weeks (~3 vials): ~9 mL → 1 bottle 16 weeks (~5 vials): ~15 mL → 2 bottles
✓Alcohol Swabs
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs 8 weeks (once daily): ~112 swabs → 1–2 boxes
KLOW protocol at a glance
A concise summary of the once-daily regimen for the combined four-peptide vial.
▪Goal: Explore the soft-tissue and anti-inflammatory pathways of four research peptides delivered together — each effect is reported preclinically for the individual components, and the combination itself is not validated in humans[5][6]. ▪Schedule: Daily subcutaneous injections for 8–12 weeks, optionally extended to ~16 weeks. ▪Dose Range: 2,667–5,333 mcg of total blend per day (~10–20 units) with gradual titration. ▪Reconstitution: 3.0 mL bacteriostatic water per 80 mg vial gives ~26.67 mg/mL; 1 unit ≈ 267 mcg total. ▪Fixed ratio: 62.5% GHK-Cu / 12.5% each BPC-157, KPV and TB-500 — components share one vial and are not independently adjustable. ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
How much KLOW per day?
A suggested daily titration approach for the combined vial, expressed as total blend. The dosage calculator at the top of this page converts any target dose into U-100 units for whatever reconstitution volume you use.
For cycle length, the week-by-week schedule and what to expect over a full cycle, see the companion KLOW cycle length & weekly schedule guide.
▪Start: Begin at 2,667 mcg total (~10 units) once daily to gauge tolerability. ▪Titrate: Step up to ~4,000 mcg (~15 units) around weeks 3–6 as tolerated. ▪Target: Reach about 5,333 mcg total (~20 units) daily by weeks 7–12. ▪Cycle Length: Typically 8–12 weeks; some research schedules extend to ~16 weeks. ▪Timing: Inject at a consistent time each day and rotate injection sites systematically. All four peptides move together — you cannot raise one without raising the rest.
How to store KLOW
Correct storage is what preserves the blend’s stability and activity.
▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7]. ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8]. ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light. ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
04 · Good to know
What should you know before using KLOW?
Practical points that keep daily administration safe and consistent.
▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward. ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9]. ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow. ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent. ▪Regulatory note: None of the four components is FDA-approved for human use, and because the blend contains BPC-157 and TB-500 it should be treated as WADA-prohibited for athletes[10].
05 · How it works
How does KLOW work?
KLOW combines four research peptides, each with a separate, mostly preclinical proposed mechanism. They are blended in one vial, but they do not act on a single shared pathway — the idea of combined “synergy” is a hypothesis, not a demonstrated effect.
GHK-Cu is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine) studied in cell and animal models for collagen synthesis, angiogenesis and skin remodelling[1].
BPC-157 is a synthetic fragment derived from a gastric protein, examined preclinically for soft-tissue and tendon repair and gut-protective effects[5].
KPV is the tripeptide Lys-Pro-Val, the C-terminal sequence of α-MSH, investigated in cell models for anti-inflammatory activity, partly via NF-κB signalling[6].
TB-500 is a synthetic fragment of Thymosin Beta-4 (the Ac-LKKTETQ region) linked in preclinical work to cell migration and angiogenesis through G-actin regulation[11][12].
Important caveat: every claim above comes from cell-culture or animal studies of the individual peptides. There are no completed human trials of this four-peptide blend, and the combination has not been shown to be safer or more effective than any component alone[13].
KLOW and its components are not approved medicines. They are unapproved research chemicals presented here for research and educational purposes only.
06 · Daily habits
What affects KLOW results?
Habits that may support recovery alongside the protocol.
▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs. ▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase. ▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes. ▪Stress: Manage stress with evidence-based practices, since it influences overall healing.
07 · What to expect
What are the benefits and side effects of KLOW?
What preclinical literature describes for the individual peptides; human evidence for the blend is absent and individual results vary.
Potential Benefits
▪Tissue repair (preclinical): GHK-Cu, BPC-157 and TB-500 are individually reported to support wound healing, collagen and angiogenesis in animal and cell models[5][6]. ▪Anti-inflammatory signalling (preclinical): KPV has shown anti-inflammatory activity via NF-κB in cell studies[11]. ▪Convenience: A single vial and one daily injection cover all four peptides, simplifying handling. ▪Note on humans: These benefits are not established in humans, and no trial has tested the four-peptide combination[13].
Common Side Effects
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps. ▪Unknown combined profile: Human safety data is absent for the blend, so caution and monitoring are advised. ▪Sport restriction: The blend contains BPC-157 and TB-500, both WADA-prohibited — treat KLOW as banned for athletes.
08 · Injection technique
How do you inject KLOW?
General subcutaneous technique, following established clinical best-practice guidance[14][15].
Preparing to inject KLOW
▪Wash your hands well with soap and water. ▪Wipe the vial stopper with an alcohol swab and let it air-dry. ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15]. ▪Draw the intended dose, then check for air bubbles and push any out.
Injecting KLOW
▪Pinch a skinfold at the chosen site between thumb and forefinger. ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14]. ▪Skip aspiration for subcutaneous shots — it isn’t needed[14]. ▪Press the plunger slowly and steadily until it’s fully down. ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
After injecting KLOW
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle. ▪Return the reconstituted vial to the fridge right away. ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9]. ▪Watch the site for excess redness, swelling, or signs of infection.
09 · Where to source
Where to source KLOW
For high-purity research peptides, we point researchers to Prime Lab Peptides for the KLOW (80 mg blend) vial.
Why Prime Lab Peptides?
▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition. ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch. ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain. ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. The product URL uses a legacy “klow-70mg” slug, but the vial and its component sum are 80 mg. Verify current product details on the supplier website.
Shop at Prime Lab Peptides →
10 · The evidence
References
1
GHK-Cu (PubMed)
Copper tripeptide GHK-Cu and its roles in collagen synthesis, angiogenesis and skin remodelling.
View Source ↗ 2
Oligopeptides & Tissue Repair (PubMed)
Review of copper-binding peptides in wound healing and regenerative signalling.
View Source ↗ 3
BPC-157 Reference Dosing
Commonly cited preclinical research dosing ranges for BPC-157 soft-tissue studies.
View Source ↗ 4
Peptide Blend Handling
General reconstitution and dosing practice for multi-peptide research vials.
View Source ↗ 5
BPC-157 (PubMed)
Body protection compound BPC-157 in preclinical soft-tissue, tendon and gut-repair models.
View Source ↗ 6
KPV / α-MSH (PubMed)
KPV tripeptide (Lys-Pro-Val), the C-terminal of α-MSH, and anti-inflammatory NF-κB signalling.
View Source ↗ 7
Peptide Storage Guide
Best practices for storing lyophilized peptides (temperature, humidity and light protection).
View Source ↗ 8
Bacteriostatic Water Guidance
Bacteriostatic water for injection: multi-dose vial stability and handling.
View Source ↗ 9
NCBI Bookshelf
Best practices for subcutaneous injection: aseptic technique and site rotation.
View Source ↗ 10
WADA Prohibited List
Classification of BPC-157 and TB-500 as prohibited substances in competitive sport.
View Source ↗ 11
KPV Anti-Inflammatory Activity (PubMed)
KPV reduces inflammation in cell and colitis models via NF-κB pathway modulation.
View Source ↗ 12
Thymosin Beta-4 / TB-500 (PubMed)
Thymosin beta-4 active fragment (TB-500): cell migration and angiogenesis via G-actin regulation.
View Source ↗ 13
ClinicalTrials.gov
Trial registry search — no completed efficacy trials of the GHK-Cu / BPC-157 / KPV / TB-500 combination.
View Source ↗ 14
Centers for Disease Control and Prevention (CDC)
Subcutaneous injection technique: angle, site and no-aspiration guidance.
View Source ↗ 15
Subcutaneous Injection Technique (Patient Education)
How to administer a subcutaneous injection: clinical technique guidelines.
View Source ↗ 16
Prime Lab Peptides
KLOW (80 mg blend) product page — purity specifications and certificates of analysis (legacy klow-70mg slug).
View Source ↗